Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
MRKR
Deeply overvalued
Marker Therapeutics, Inc.
Price$1.17
Model IV$0.56
P/IV2.79
Premium +108%
Return to IV: -51.9%
Market implies +4.5%/yr
vs model +30.0% · below model
MRNA
Valuation N/A
Moderna, Inc.
Price$154.04
Model IV—
P/IV—
Market implies +74.5%/yr
vs model +2.0% · above model
MRVI
Valuation N/A
MARAVAI LIFESCIENCES HOLDINGS, INC.
Price$6.53
Model IV—
P/IV—
Market implies +55.5%/yr
vs model +2.0% · above model
MSA
Overvalued
MSA Safety Inc
Price$178.79
Model IV$154.44
P/IV1.07
Premium +16%
Return to IV: -13.6%
Owner yield 2.8%
10-yr IRR 2.3% · moderate
Market implies +8.9%/yr
vs model +8.3% · in line
MSAI
Valuation N/A
MultiSensor AI Holdings, Inc.
Price$4.81
Model IV—
P/IV—
Market implies +99.1%/yr
vs model +2.0% · above model
MSLE
Valuation N/A
Satellos Bioscience Inc.
Price$9.75
Model IV—
P/IV—
MTD
Deeply overvalued
METTLER TOLEDO INTERNATIONAL INC/
Price$1,392.32
Model IV$792.57
P/IV1.49
Premium +76%
Return to IV: -43.1%
Owner yield 3.0%
10-yr IRR 2.5% · moderate
Market implies +13.8%/yr
vs model +7.5% · above model
MTEX
Deeply undervalued
MANNATECH INC
Price$8.21
Model IV$83.16
P/IV0.07
Discount 90%
Return to IV: +912.9%
Market implies -50.0%/yr
vs model +2.0% · below model
MTNB
Valuation N/A
Matinas BioPharma Holdings, Inc.
Price$0.19
Model IV—
P/IV—
Market implies -8.9%/yr
vs model +15.0% · below model
MTVA
Valuation N/A
MetaVia Inc.
Price$1.58
Model IV—
P/IV—
MYGN
Deeply undervalued
MYRIAD GENETICS INC
Price$3.42
Model IV$9.25
P/IV0.43
Discount 63%
Return to IV: +170.6%
Market implies -16.6%/yr
vs model +4.5% · below model
MYO
Overvalued
MYOMO, INC.
Price$1.24
Model IV$0.97
P/IV1.59
Premium +28%
Return to IV: -21.9%
Market implies +1.2%/yr
vs model +15.0% · below model
NAGE
Deeply overvalued
Niagen Bioscience, Inc.
Price$3.04
Model IV$1.72
P/IV2.24
Premium +77%
Return to IV: -43.4%
Market implies +19.1%/yr
vs model +15.4% · above model
NAII
Undervalued
NATURAL ALTERNATIVES INTERNATIONAL INC
Price$1.96
Model IV$2.99
P/IV0.85
Discount 35%
Return to IV: +52.7%
Market implies -6.2%/yr
vs model +3.7% · below model
NAMS
Valuation N/A
NewAmsterdam Pharma Co N.V.
Price$22.80
Model IV—
P/IV—
Market implies +69.3%/yr
vs model +15.0% · above model
NAMSW
Valuation N/A
NewAmsterdam Pharma Co N.V.
Price$11.49
Model IV—
P/IV—
Market implies +42.1%/yr
NATR
Deeply undervalued
NATURES SUNSHINE PRODUCTS INC
Price$13.55
Model IV$34.14
P/IV0.62
Discount 60%
Return to IV: +152.0%
Owner yield 9.9%
10-yr IRR 19.0% · moderate
Market implies -6.7%/yr
vs model +6.8% · below model
NAUT
Valuation N/A
Nautilus Biotechnology, Inc.
Price$1.02
Model IV—
P/IV—
NBIX
Deeply undervalued
NEUROCRINE BIOSCIENCES INC
Price$156.22
Model IV$244.63
P/IV0.65
Discount 36%
Return to IV: +56.6%
Owner yield 3.5%
10-yr IRR 9.9% · grower
Market implies +10.1%/yr
vs model +21.2% · below model
NBP
Valuation N/A
NovaBridge Biosciences
Price$1.59
Model IV—
P/IV—
Market implies +88.8%/yr
vs model +15.0% · above model
NBTX
Valuation N/A
Nanobiotix S.A.
Price$35.73
Model IV—
P/IV—
NCEL
Valuation N/A
NewcelX Ltd.
Price$3.30
Model IV—
P/IV—
NCNA
Valuation N/A
NuCana plc
Price$1.32
Model IV—
P/IV—
NDRA
Valuation N/A
ENDRA Life Sciences Inc.
Price$5.62
Model IV—
P/IV—
NEOG
Deeply overvalued
NEOGEN CORP
Price$11.78
Model IV$6.67
P/IV1.35
Premium +77%
Return to IV: -43.4%
Market implies +8.2%/yr
vs model +17.6% · below model
NEPH
Fairly valued
NEPHROS INC
Price$4.06
Model IV$3.98
P/IV0.92
Premium +2%
Return to IV: -2.1%
Market implies +7.8%/yr
vs model +14.5% · below model
NERV
Valuation N/A
Minerva Neurosciences, Inc.
Price$3.83
Model IV—
P/IV—
NEUP
Deeply undervalued
Neuphoria Therapeutics Inc.
Price$3.73
Model IV$16.13
P/IV0.33
Discount 77%
Return to IV: +332.5%
Market implies -31.6%/yr
vs model +15.0% · below model
NGEN
Valuation N/A
NERVGEN PHARMA CORP.
Price$2.20
Model IV—
P/IV—
NGNE
Valuation N/A
Neurogene Inc.
Price$37.61
Model IV—
P/IV—
Market implies +106.3%/yr
vs model +15.0% · above model
NHC
Deeply undervalued
NATIONAL HEALTHCARE CORP
Price$218.64
Model IV$281.11
P/IV0.66
Discount 22%
Return to IV: +28.6%
Owner yield 3.0%
10-yr IRR 5.1% · moderate
Market implies +5.2%/yr
vs model +10.8% · below model
NIVF
Valuation N/A
NewGenIvf Group Ltd
Price$1.06
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +50.0% · below model
NIVFW
Valuation N/A
NewGenIvf Group Ltd
Price$0.02
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +11.7% · below model
NKTR
Valuation N/A
NEKTAR THERAPEUTICS
Price$68.50
Model IV—
P/IV—
Market implies +95.7%/yr
vs model +2.0% · above model
NKTX
Valuation N/A
Nkarta, Inc.
Price$2.92
Model IV—
P/IV—
NMRA
Valuation N/A
Neumora Therapeutics, Inc.
Price$1.14
Model IV—
P/IV—
NMTC
Fairly valued
NEUROONE MEDICAL TECHNOLOGIES Corp
Price$1.56
Model IV$1.66
P/IV2.14
Discount 6%
Return to IV: +6.3%
Market implies -7.9%/yr
vs model +50.0% · below model
NNNN
Valuation N/A
Anbio Biotechnology
Price$6.54
Model IV—
P/IV—
Market implies +34.1%/yr
vs model +2.0% · above model
NNOX
Valuation N/A
Nano-X Imaging Ltd.
Price$0.70
Model IV—
P/IV—
NNVC
Valuation N/A
NANOVIRICIDES, INC.
Price$1.12
Model IV—
P/IV—
NPCE
Deeply overvalued
NeuroPace Inc
Price$14.04
Model IV$4.76
P/IV3.47
Premium +195%
Return to IV: -66.1%
Market implies +14.4%/yr
vs model +22.0% · below model
NRIX
Valuation N/A
Nurix Therapeutics, Inc.
Price$24.83
Model IV—
P/IV—
Market implies +35.5%/yr
vs model +29.6% · above model
NRSN
Valuation N/A
NeuroSense Therapeutics Ltd.
Price$6.90
Model IV—
P/IV—
NRSNW
Valuation N/A
NeuroSense Therapeutics Ltd.
Price$0.05
Model IV—
P/IV—
NRXP
Valuation N/A
NRX Pharmaceuticals, Inc.
Price$3.40
Model IV—
P/IV—
Market implies +74.4%/yr
vs model +15.0% · above model
NRXS
Valuation N/A
Neuraxis, INC
Price$5.74
Model IV—
P/IV—
Market implies +32.9%/yr
vs model +10.0% · above model
NSPR
Deeply overvalued
InspireMD, Inc.
Price$0.79
Model IV$0.21
P/IV4.38
Premium +276%
Return to IV: -73.4%
Market implies +11.5%/yr
vs model +18.9% · below model
NSRX
Valuation N/A
Nasus Pharma Ltd
Price$3.59
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +15.0% · below model
NTHI
Valuation N/A
NEONC TECHNOLOGIES HOLDINGS, INC.
Price$3.31
Model IV—
P/IV—
Market implies +130.0%/yr
vs model +2.0% · above model
NTLA
Valuation N/A
Intellia Therapeutics, Inc.
Price$11.74
Model IV—
P/IV—
Market implies +53.6%/yr
vs model +19.6% · above model
NTRA
Deeply overvalued
Natera, Inc.
Price$328.93
Model IV$89.11
P/IV2.51
Premium +269%
Return to IV: -72.9%
Market implies +16.6%/yr
vs model +38.6% · below model
NTRB
Valuation N/A
NutriBand Inc.
Price$6.96
Model IV—
P/IV—
Market implies +42.4%/yr
vs model +14.6% · above model
NTRBW
Valuation N/A
NutriBand Inc.
Price$0.60
Model IV—
P/IV—
NUVB
Valuation N/A
Nuvation Bio Inc.
Price$5.94
Model IV—
P/IV—
Market implies -50.0%/yr
vs model +15.0% · below model
NUVL
Valuation N/A
Nuvalent, Inc.
Price$123.96
Model IV—
P/IV—
NUWE
Valuation N/A
Nuwellis, Inc.
Price$0.77
Model IV—
P/IV—
Market implies -36.3%/yr
vs model +2.0% · below model
NVAX
Valuation N/A
NOVAVAX INC
Price$9.42
Model IV—
P/IV—
Market implies +37.0%/yr
vs model +2.0% · above model
NVCR
Valuation N/A
NovoCure Ltd
Price$16.22
Model IV—
P/IV—
Market implies +35.6%/yr
vs model +5.2% · above model
NVCT
Valuation N/A
Nuvectis Pharma, Inc.
Price$23.99
Model IV—
P/IV—
NVMI
Valuation N/A
NOVA LTD.
Price$371.81
Model IV—
P/IV—